{"pub": "reuters", "url": "https://uk.reuters.com/article/uk-britain-stocks/ftse-100-on-track-for-fourth-session-of-gains-idUKKBN1X30OV", "downloaded_at": "2019-10-24 09:54:02.552324+00:00", "title": "FTSE 100 on track for fourth session of gains", "language": "en", "text": "(Reuters) - London\u2019s FTSE 100 rose on Thursday along with its European counterparts, helped by strong French manufacturing data and gains in AstraZeneca after a 2019 forecast upgrade.\n\nTraders are seen at work at Northern Trust offices in London, Britain August 1, 2019. REUTERS/Toby Melville/Files\n\nThe blue-chip index .FTSE climbed 0.7% to a near one-month high by 0730 GMT, on course for its fourth session of gains. A dip in sterling limited the FTSE 250 .FTMC to a 0.2% gain.\n\nAfter rising to session highs following data from France, the main bourse eased slightly after another survey showed employment in Germany\u2019s private sector fell for the first time in six years in October.\n\nThe conflicting data come at a time of existing fears over global economic growth, as multiple unfavourable events including the U.S.-China trade tussle and Brexit play out.\n\nIn the past two weeks UK shares have been volatile with major Brexit developments including Prime Minister Boris Johnson striking a new Brexit deal with the European bloc and lawmakers at home forcing his hand into asking for another extension to the divorce.\n\n\u2018U.S.-CHINA AND BREXIT IN LIMBO\u2019\n\nThe FTSE 100, whose components rake in more than two-thirds of their earnings in U.S. dollars, is on course for its best weekly gain since early June, as uncertainties over the course of UK\u2019s EU departure have dented the value of sterling.\n\nAstraZeneca (AZN.L) gained 3%, its biggest one-day rise in three months, after the pharmaceutical giant raised its annual product sales forecast for the second time this year.\n\nAnalytics and decision tools provider Relx (REL.L) and industrial software company Aveva (AVV.L) added 2.5% each following trading updates.\n\n\u201cThere\u2019s not been a huge catalyst for markets this week. Earnings are largely topping beaten-down estimates. U.S.-China and Brexit are in limbo,\u201d Markets.com analyst Neil Wilson said.\n\nOn the other end of the spectrum was Royal Bank of Scotland (RBS.L) that skidded 3% as it swung to a third-quarter loss due to a fresh 900 million pound provision to settle mis-selling claims.\n\nA notable mid-cap performer was Kaz Minerals (KAZ.L) that jumped 7% after record third-quarter copper production as it ramped up operations at its biggest mines in Kazakhstan.\n\nWoodford Patient Capital Trust (WPCT.L), formerly run by high-profile money manager Neil Woodford, jumped 22% as the company appointed asset manager Schroders (SDR.L) as its new portfolio manager.", "description": "London's FTSE 100 rose on Thursday along with its European counterparts, helped by strong French manufacturing data and gains in AstraZeneca after a 2019 forecast upgrade.", "authors": ["Muvija M", "Min Read"], "top_image": "https://s4.reutersmedia.net/resources/r/?m=02&d=20191024&t=2&i=1444403884&w=1200&r=LYNXMPEF9N0FV", "published_at": "2019-10-24"}